LOQUS23 THERAPEUTICS

About:

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease.

Top Investors: Forbion Capital Partners, SV Health Investors, Dementia Discovery Fund, Novartis Venture Fund

Description:

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.

Total Funding Amount:

46.5M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2019-01-01

Founders:

David Reynolds

Number of Employees:

1-10

Last Funding Date:

2024-10-02

IPO Status:

Private

Industries: